Wednesday, August 26, 2026 1 PM-2 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology, and Molly Epler, MHI, LSSYB, Clinical Laboratory Manager, Wexner Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 23, 2026. 12 PM-12:30 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2026—Beckman Coulter Diagnostics has launched in the U.S. its DxU 1800 system, a fully automated urinalysis solution that combines the new DxU 1800c chemistry analyzer with a DxU Iris microscopy analyzer.
August 2026—Diazyme Laboratories has acquired Carolina Liquid Chemistries Corp., an FDA-registered manufacturer and reseller of chemistry systems and reagents.
August 2026—Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii, a targeted plasma cell-free DNA liquid biopsy assay for the detection of P. jirovecii, and the FungiFlex Mold Plus panel, which combines invasive mold detection with P. jirovecii in a single plasma-based test order.
August 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing. MDx-Chex for BCY, MDx-Chex for BCP, and MDx-Chex for BCN are patient-like, ready-to-use, full-process molecular quality controls designed for verification of the Diasorin Liaison Plex yeast, Gram-positive, and Gram-negative blood culture assays, respectively. The controls are supplied in 10 single-use vial kits and feature room-temperature storage.
August 2026—Pictor Holdings debuted its next-generation high-resolution platform, the PictImager, at the Association for Diagnostics and Laboratory Medicine Annual Meeting and Clinical Lab Expo (July 26–30, Anaheim, Calif.).
August 2026—Werfen and Oxford Nanopore Technologies have entered a strategic collaboration to validate Werfen’s transplant assay portfolio, including solutions for human leukocyte antigen typing and pretransplant matching, for use on Oxford Nanopore sequencing platforms.
August 2026—Clarapath launched TrimStar Pro, an FDA-registered facing and trimming solution designed to help histology laboratories take a step toward automation.
August 2026—At the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE), artificial intelligence research in disease detection begins with a practical reality: most of the data still lives on glass.
July 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion (SBX) technology. The platform converts DNA or RNA into high signal‑to‑noise Xpandomers, which are measured by a sequencing instrument using a reusable complementary metal-oxide semiconductor sensor containing millions of nanopores.
July 2026—The FDA has granted 510(k) clearance for Diazyme Laboratories’ Lipoprotein(a) Molarity assay for use in the quantitative determination of Lp(a) levels in human serum and plasma, reported in molar units (nmol/L).
